Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M
Research Centre of Obstetrics, Gynaecology and Perinatology, Russian Academy of the Medical Sciences, Moscow, Russia.
Reproduction. 2006 Sep;132(3):501-9. doi: 10.1530/rep.1.01110.
Studies were performed to elucidate the possible relationship between microvessel density, proliferative activity and angiogenesis in eutopic endometrium from women with and without endometriosis and peritoneal endometriotic lesions. The question whether changes in these parameters in endometriotic lesions were reflected by the level of vascular endothelial growth factor-A (VEGF-A) in serum and peritoneal fluid was also studied. Biopsy specimens of both eutopic endometrium and peritoneal endometriotic lesions from women with endometriosis (n = 25) as well as eutopic endometrium from women without endometriosis (n = 14) were analysed immunohistochemically regarding microvessel density, proliferative activity, and expression of VEGF-A and its receptors vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2) in stroma, glands and blood vessels. The VEGF-A concentration was measured in peritoneal fluid and serum. Secretory phase eutopic endometrium from women with endometriosis had significantly higher microvessel density, expression of VEGF-A in glandular epithelium and VEGFR-2 in endometrial blood vessels than those from women without endometriosis. Endometriotic lesions with high proliferative activity had a higher microvessel density and showed higher vascular expression of VEGFR-2 as well as being accompanied by higher levels of VEGF-A in peritoneal fluid and serum, compared with lesions with low proliferative activity. In conclusion, there seems to be a dysregulation of angiogenic activity in the eutopic endometrium of women with endometriosis and endometriotic lesions with high proliferative activity were accompanied by higher local angiogenic activity and higher levels of VEGF in serum and peritoneal fluid.
开展了多项研究，以阐明患有和未患有子宫内膜异位症及腹膜子宫内膜异位病变的女性在位内膜中微血管密度、增殖活性和血管生成之间的可能关系。还研究了血清和腹水中血管内皮生长因子-A（VEGF-A）水平是否反映了子宫内膜异位病变中这些参数的变化。对患有子宫内膜异位症的女性（n = 25）的在位内膜和腹膜子宫内膜异位病变以及未患有子宫内膜异位症的女性（n = 14）的在位内膜活检标本进行免疫组织化学分析，检测其微血管密度、增殖活性以及VEGF-A及其受体血管内皮生长因子受体1和2（VEGFR-1和VEGFR-2）在基质、腺体和血管中的表达。检测了腹水和血清中的VEGF-A浓度。患有子宫内膜异位症的女性分泌期在位内膜的微血管密度、腺上皮中VEGF-A的表达以及子宫内膜血管中VEGFR-2的表达均显著高于未患有子宫内膜异位症的女性。与增殖活性低的病变相比，增殖活性高的子宫内膜异位病变微血管密度更高，VEGFR-2的血管表达更高，并伴有腹水和血清中更高水平的VEGF-A。总之，患有子宫内膜异位症的女性在位内膜似乎存在血管生成活性失调，增殖活性高的子宫内膜异位病变伴有更高的局部血管生成活性以及血清和腹水中更高水平的VEGF。
